On the 30th, the State Medical Security Bureau and the State Administration of traditional Chinese Medicine issued guidance on medical insurance supporting the inheritance, innovation and development of traditional Chinese medicine. The opinions put forward that it is required to include qualified pieces of traditional Chinese medicine, proprietary Chinese medicine and traditional Chinese medicine preparations of medical institutions into the catalogue of Medicare drugs.
In recent years, the state has intensively launched various policies to support and encourage the inheritance, innovation and development of traditional Chinese medicine: the number of Chinese patent medicines in the basic medicine catalogue accounts for 39.12%, and the continuous promotion of the “986” goal is expected to stimulate the large-scale production of traditional Chinese medicine. Since 2021, the approval of innovative Chinese traditional medicine has accelerated. As of December 24, 2021, 11 innovative Chinese patent medicines have been approved. Recently, the ex factory prices of Beijing Tongrentang Co.Ltd(600085) Angong Niuhuang Pill and Chongqing Taiji Industry (Group) Co.Ltd(600129) Huoxiang Zhengqi oral liquid have increased, which has aroused the market’s attention to the price raising ability of brand traditional Chinese medicine.
According to the theme database of financial Associated Press, among the relevant listed companies:
Tibet Cheezheng Tibetan Medicine Co.Ltd(002287) has 55 Tibetan medicine varieties and 72 approval numbers with 12 exclusive varieties or exclusive dosage forms such as Xiaotong patch and Baimai ointment as the core, including 9 OTC varieties and 2 national secret technology (secret level) varieties.
Guangdong Jiangxi Wannianqing Cement Co.Ltd(000789) has 101 drug approvals, covering 13 drug fields such as biliary tract, hypoglycemic, heat clearing and detoxification, gynecology and tonic.
(Financial Associated Press)
